

# NeuroPerspective Index

*This index lists the main therapeutic area covered; some of the companies whose programs are covered; and the Company Spotlight feature. Many other subtopics, analyses, and events are reviewed in each issue.*

DATE	FEATURE TOPIC	COMPANIES INCLUDED
<b>2016</b>		
Jan-Feb	<b>Review 2015</b>	Preview of 2016/ <i>Spotlight: Minerva Neurosciences</i>
Mar-April	<b>Depression</b>	Allergan, JNJ, Cerecor, others/ <i>Spotlight: NeuroRx</i>
	<b>Autism</b>	BioAxone/Vertex, NeuralStem, others/ <i>Spotlight: Annexon</i>
May-June	<b>Stroke</b>	NoNo, SanBio, Edge: <i>Spotlight: Zocere</i>
	<b>TBI</b>	Neuren, ALSP, EverNeuro, Remedy, others: <i>Spotlight: ALSP</i>
July-August	<b>MidYear Review/Preview</b>	80+ companies/ <i>Spotlight: AC Immune</i>
	<b>Migraine</b>	Amgen/Novartis, Teva, Lilly, Alder, more
Sept-October	<b>Alzheimer's</b>	Roche, AC Immune, TauRx, Axon-Neuro / <i>Spotlight: Klogene</i>
	<b>MCI</b>	Axovant, AgeneBio, more / <i>NL Excerpt: Sunovion</i>
Nov-Dec	<b>Multiple Sclerosis</b>	Biogen, Teva, Sanofi, more / <i>NL Excerpt: JNJ</i>
	<b>Pain</b>	Egalent, Cara, Trevena, Depomed, more/ <i>Spotlight: Centrexion</i>
<b>2015</b>		
Jan-Feb	<b>Review 2014</b>	Preview of 2015/ <i>Spotlight: Heptares</i>
Mar-April	<b>Schizophrenia</b>	Forum, Roche, Minerva, others/ <i>Spotlight: Tetra Discovery</i>
	<b>Spinal Cord Injury</b>	BioAxone/Vertex, NeuralStem, others/ <i>Spotlight: BioAxone</i>
May-June	<b>Parkinson's</b>	MedGenesis, Acorda, others/ <i>Spotlight: Cynapsus</i>
	<b>Neuropathic Pain</b>	Spinifex, Pfizer, others/ <i>Spotlight: MedGenesis</i>
July-August	<b>MidYear Review/Preview</b>	80+ companies/ <i>Spotlight: Marinus Pharma</i>
	<b>ALS</b>	NeuralStem, Neuraltus, Cytokinetics, more
Sept-October	<b>Alzheimer's</b>	Roche, AC Immune, TauRx / <i>Spotlight: Axon-Neuroscience</i>
	<b>MCI</b>	Axovant, AgeneBio, others / <i>Spotlight: AgeneBio</i>
Nov-Dec	<b>Addictions</b>	Embera, AstraZeneca, more / <i>Spotlight: Embera</i>
	<b>NeuroInnovation</b>	Sector overview/ <i>Spotlight: InterVeXion</i>
<b>2014</b>		
January	<b>Review of 2013</b>	Preview of 2014/ <i>Spotlight: Lysosomal Therapeutics</i>
February	<b>Multiple Sclerosis</b>	Biogen, Teva, XenoPort, more/ <i>Spotlight: Canbex</i>
March	<b>Huntington's</b>	Isis, Roche, Proteostasis, more/ <i>Spotlight: Prana</i>
April	<b>Migraine</b>	Labrys, Alder, Amgen, Lilly, others/ <i>Spotlight: Depomed</i>
May	<b>Depression</b>	Naurex, Alkermes, Roche, others/ <i>Spotlight: Biocrea</i>
June	<b>Pain</b>	Spinifex, Afferent, Pfizer, others/ <i>Spotlight: Spinifex</i>
July-August	<b>MidYear Review/Preview</b>	Sector Overview/ <i>Spotlight: BioTie</i>
September	<b>Alzheimer's</b>	Roche, AC Immune, TauRx, others / <i>Spotlight: Neuronascent</i>
October	<b>ADHD</b>	Alcobra, Shire, others / <i>Licensing Spotlight: AstraZeneca</i>
November	<b>Epilepsy</b>	Roche, Novartis, Marinus / <i>Licensing Spotlight: Pfizer</i>
December	<b>Rett Syndrome/FTD</b>	Neuren, Forum, others / <i>Spotlight: Neuren</i>